Xifaxan He denied as experimental or investigational by Cigna?

Cigna's specific coverage criteria for xifaxan he are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Cigna Denied This as Experimental

An "experimental or investigational" denial for rifaximin (Xifaxan) used for hepatic encephalopathy (HE) is unusual given the drug's FDA-approved indication for this use, but it does occur — typically when the specific clinical context (e.g., a particular HE stage, a comorbid condition, or a combination regimen) falls outside the language Cigna uses in its internal coverage policy, or when the policy has not been recently updated to reflect current medical consensus.

This type of denial is one of the most appealable categories because FDA approval for the relevant indication creates a strong factual counter-argument. Cigna bears the burden of explaining why a federally approved use is nonetheless experimental under their policy.

## Why This Is Appealable

• FDA approval is a concrete counter-fact: Rifaximin carries FDA approval for reducing the risk of overt HE recurrence in adults. Your appeal should explicitly reference this approval status. You can verify the current approved indication on the FDA label, which is publicly available at DailyMed (dailymed.nlm.nih.gov).
• ACA §2719 external review: Non-grandfathered plans must offer independent external review. An external reviewer — a clinician with no relationship to Cigna — evaluates whether the denial was clinically reasonable. Experimental denials of FDA-approved drugs are often reversed at this stage. You have approximately four months from the denial to request external review; confirm the exact date on your EOB.
• ERISA §503: Employer plans must provide the specific criteria and evidence used to classify the treatment as experimental, allowing you to rebut each point.
• Expedited review: Available if standard timelines would seriously harm your health.

## Documentation to Gather

• FDA label / prescribing information: Print the current FDA-approved label for rifaximin from DailyMed and attach it to your appeal. Highlight the HE indication section.
• Diagnosis and severity records: Chart notes confirming your HE diagnosis, including any episodes, hospitalizations, or documented cognitive assessments.
• Prescriber's medical-necessity letter: Your physician should explicitly state the FDA-approved indication being treated, reference the relevant hepatology society guideline organization, and explain why this is established, non-experimental care for your presentation.
• Prior-treatment history: Documentation of any previous HE treatments, responses, and the clinical rationale for adding or switching to rifaximin.

## Criteria-Mapping Approach

Pull Cigna's coverage policy for rifaximin and locate the exact language defining what makes a treatment "experimental." Map each element of that definition to the facts that contradict it: the FDA approval date and indication, published consensus guidelines from the relevant hepatology society, and your prescriber's attestation that this is standard-of-care treatment for your specific clinical scenario. A point-by-point rebuttal is far more effective than a general objection.